Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 111

1.

A double-blind, randomized, controlled study to explore the efficacy of rFVIIa on intraoperative blood loss and mortality in patients with severe acute pancreatitis.

Lu J, Liao LM, Geng YX, Wang X, Tong ZH, Ke L, Li WQ, Li N, Li JS.

Thromb Res. 2014 Apr;133(4):574-8. doi: 10.1016/j.thromres.2014.01.009.

PMID:
24457144
2.

Recombinant coagulation factor VIIa in major liver resection: a randomized, placebo-controlled, double-blind clinical trial.

Lodge JP, Jonas S, Oussoultzoglou E, Malagó M, Jayr C, Cherqui D, Anthuber M, Mirza DF, Kuhlman L, Bechstein WO, Díaz JC, Tartiere J, Eyraud D, Fridberg M, Erhardtsen E, Mimoz O.

Anesthesiology. 2005 Feb;102(2):269-75.

PMID:
15681939
4.

Recombinant activated factor VII in spinal surgery: a multicenter, randomized, double-blind, placebo-controlled, dose-escalation trial.

Sachs B, Delacy D, Green J, Graham RS, Ramsay J, Kreisler N, Kruse P, Khutoryansky N, Hu SS.

Spine (Phila Pa 1976). 2007 Oct 1;32(21):2285-93.

PMID:
17906567
5.

Recombinant activated factor VII (NovoSeven): addition to replacement therapy in acute, uncontrolled and life-threatening bleeding.

Mayo A, Misgav M, Kluger Y, Geenberg R, Pauzner D, Klausner J, Ben-Tal O.

Vox Sang. 2004 Jul;87(1):34-40. Review.

PMID:
15260820
6.

Methods to decrease blood loss and transfusion requirements for liver transplantation.

Gurusamy KS, Pissanou T, Pikhart H, Vaughan J, Burroughs AK, Davidson BR.

Cochrane Database Syst Rev. 2011 Dec 7;(12):CD009052. doi: 10.1002/14651858.CD009052.pub2. Review.

PMID:
22161443
7.

Recombinant activated factor VII in patients with acute liver failure with UNOS Status 1A: a single tertiary academic centre experience.

Pham HP, Hsu SX, Parker-Jones S, Samstein B, Diuguid D, Schwartz J.

Vox Sang. 2014 Jan;106(1):75-82. doi: 10.1111/vox.12067.

PMID:
23815226
9.

Use of recombinant factor VIIa (NovoSeven) in pediatric cardiac surgery.

Niles SD, Burkhart HM, Duffey DA, Buhrman K, Burzynski J, Holt DW.

J Extra Corpor Technol. 2008 Dec;40(4):241-8.

10.

Use of recombinant activated Factor VII for refractory after lung transplant bleeding as an effective strategy to restrict blood transfusion and associated complications.

Bhaskar B, Zeigenfuss M, Choudhary J, Fraser JF.

Transfusion. 2013 Apr;53(4):798-804. doi: 10.1111/j.1537-2995.2012.03801.x.

PMID:
22845023
11.

[The use of recombinant activated factor VIIa for major bleedings in open heart surgery].

Ingimarsson JP, Onundarson PT, Valsson F, Vidarsson B, Gudbjartsson T.

Laeknabladid. 2008 Sep;94(9):607-12. Icelandic.

PMID:
18784387
12.

Use of recombinant activated factor VII for bleeding in pancreatitis: a case series.

Laffan MA, Tait RC, Blatný J, Espersen K, Grabowska I, Loch-Bakoñska L, Pauzkowska A, Stasiak-Pikula E, Michalska G, Wendon J, Piotrowska K.

Pancreas. 2005 Apr;30(3):279-84.

PMID:
15782108
13.

Role of recombinant factor VIIa in the treatment of intractable bleeding in vascular surgery.

Končar IB, Davidović LB, Savić N, Sinđelić RB, Ilić N, Dragas M, Markovic M, Kostic D.

J Vasc Surg. 2011 Apr;53(4):1032-7. doi: 10.1016/j.jvs.2010.07.075.

14.

Recombinant activated factor VII as an adjunctive therapy for bleeding control in severe trauma patients with coagulopathy: subgroup analysis from two randomized trials.

Rizoli SB, Boffard KD, Riou B, Warren B, Iau P, Kluger Y, Rossaint R, Tillinger M; NovoSeven Trauma Study Group..

Crit Care. 2006;10(6):R178.

15.

Intraoperative use of recombinant activated factor VII (rFVIIa).

De Gasperi A.

Minerva Anestesiol. 2006 Jun;72(6):489-94. Review.

16.

Single-center experience: use of recombinant factor VIIa for acute life-threatening bleeding in children without congenital hemorrhagic disorder.

Yilmaz D, Karapinar B, Balkan C, Akisü M, Kavakli K.

Pediatr Hematol Oncol. 2008 Jun;25(4):301-11. doi: 10.1080/08880010802016904.

PMID:
18484474
17.

Exploratory study on the reversal of warfarin with rFVIIa in healthy subjects.

Skolnick BE, Mathews DR, Khutoryansky NM, Pusateri AE, Carr ME.

Blood. 2010 Aug 5;116(5):693-701. doi: 10.1182/blood-2009-11-253492. Erratum in: Blood. 2010 Dec 2;116(23):5079.

18.

Recombinant factor VIIa as last-resort treatment of desperate haemorrhage.

Palmason R, Vidarsson B, Sigvaldason K, Ingimarsson JP, Gudbjartsson T, Sigurdsson GH, Onundarson PT.

Acta Anaesthesiol Scand. 2012 May;56(5):636-44. doi: 10.1111/j.1399-6576.2012.02688.x.

PMID:
22489992
19.

Single pretransplant bolus of recombinant activated factor VII ameliorates influence of risk factors for blood loss during orthotopic liver transplantation.

Kaliciński P, Markiewicz M, Kamiński A, Laniewski P, Ismail H, Drewniak T, Szymczak M, Nachulewicz P, Jezierska E.

Pediatr Transplant. 2005 Jun;9(3):299-304.

PMID:
15910384
20.

Efficacy and safety of repeated perioperative doses of recombinant factor VIIa in liver transplantation.

Lodge JP, Jonas S, Jones RM, Olausson M, Mir-Pallardo J, Soefelt S, Garcia-Valdecasas JC, McAlister V, Mirza DF; rFVIIa OLT Study Group..

Liver Transpl. 2005 Aug;11(8):973-9.

Items per page

Supplemental Content

Support Center